Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 251, Issue 4, 2013, Pages 1073-1080

  Nakata, Isao ^a   Tsujikawa, Akitaka ^a   Yamashiro, Kenji ^a   Otani, Atsushi ^a   Ooto, Sotaro ^a   Akagi Kurashige, Yumiko ^a   Ueda Arakawa, Naoko ^a   Iwama, Daisuke ^a   Yoshimura, Nagahisa ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Age related macular degeneration; Bevacizumab; Photodynamic therapy; Polypoidal choroidal vasculopathy; Triamcinolone acetonide

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE ACETONIDE; VERTEPORFIN;

AGED; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; TREATMENT RESPONSE; VISUAL ACUITY; VITREOUS HEMORRHAGE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROID; CHOROID DISEASES; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MALE; PHOTOCHEMOTHERAPY; POLYPS; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 84876675515     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-012-2137-y     Document Type: Article

References (34)

1. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, Lewis H, Schmidt-Erfurth U, Slakter JS, Bressler SB, Manos K, Hao Y, Hayes L, Koester J, Reaves A, Strong HA (2002) Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP report No. 3. Arch Ophthalmol 120:1443-1454 (Pubitemid 36406418)
2. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372, e365
3. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113(633):e631-e634
4. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035-1047 (Pubitemid 40797459)
5. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897-1908
6. Ahmadieh H, Taei R, Soheilian M, Riazi-Esfahani M, Karkhaneh R, Lashay A, Azarmina M, Dehghan MH, Moradian S (2007) Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmol 7:10 (Pubitemid 47025082)
7. Yip PP, Woo CF, Tang HH, Ho CK (2009) Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. Br J Ophthalmol 93:754-758
8. Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA (2004) Polypoidal choroidal vasculopathy. Surv Ophthalmol 49:25-37 (Pubitemid 38056622)
9. Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, Nishikawa M, Mitsuma Y, Yamazaki Y, Matsumura M, Uyama M (2003) Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol 121:1392-1396 (Pubitemid 37243739)
10. Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15-22 (Pubitemid 46963198)
11. Kokame GT, Yeung L, Lai JC (2010) Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol 94:297-301
12. Hikichi T, Ohtsuka H, Higuchi M, Matsushita T, Ariga H, Kosaka S, Matsushita R, Takami K (2010) Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months. Am J Ophthalmol 150:674-682, e671
13. Spaide RF, Donsoff I, Lam DL, Yannuzzi LA, Jampol LM, Slakter J, Sorenson J, Freund KB (2002) Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 22:529-535 (Pubitemid 35176066)
14. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y, Ikuno Y, Tano Y (2008) One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 115:141-146 (Pubitemid 350309415)
15. Tsuchiya D, Yamamoto T, Kawasaki R, Yamashita H (2009) Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina 29:960-965
16. Yamashiro K, Tsujikawa A, Nishida A, Mandai M, Kurimoto Y (2008) Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy. Jpn J Ophthalmol 52:457-462
17. Kurashige Y, Otani A, Sasahara M, Yodoi Y, Tamura H, Tsujikawa A, Yoshimura N (2008) Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 146:513-519
18. Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M (2010) Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 150:48-54
19. Sato T, Kishi S, Matsumoto H, Mukai R (2010) Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol 149:947-995
20. Ruamviboonsuk P, Tadarati M, Vanichvaranont S, Hanutsaha P, Pokawattana N (2010) Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study. Br J Ophthalmol 94:1045-1051
21. Obata R, Iriyama A, Inoue Y, Takahashi H, Tamaki Y, Yanagi Y (2007) Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro. Br J Ophthalmol 91:100-104 (Pubitemid 46094019)
22. Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P (2002) Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 240:42-48 (Pubitemid 36075572)
23. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 117:1329-1345
24. Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H, Tsujikawa A, Yoshimura N (2007) Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 144:7-14 (Pubitemid 46963181)
25. Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ (2011) One-year outcomes of intravitreal bevacizumab (Avastin) therapy for polypoidal choroidal vasculopathy. Retina 31:846-856
26. Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, Wong TH (2004) Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 111:1576-1584 (Pubitemid 39030815)
27. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473-4480 (Pubitemid 37186285)
28. Tatar O, Adam A, Shinoda K, Stalmans P, Eckardt C, Luke M, Bartz-Schmidt KU, Grisanti S (2006) Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 142:95-104 (Pubitemid 43949615)
29. Okubo A, Ito M, Kamisasanuki T, Sakamoto T (2005) Visual improvement following trans-Tenon's retrobulbar triamcinolone acetonide infusion for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 243:837-839 (Pubitemid 41300429)
30. Mukai R, Kishi S, Sato T, Watanabe G, Matsumoto H (2010) Protective effect of intravitreal bevacizumab and sub-tenon triamcinolone acetonide against occlusion of choriocapillaris induced by photodynamic therapy. Ophthalmologica 224:267-273
31. Lai TY, Lam CP, Luk FO, Chan RP, Chan WM, Liu DT, Lam DS (2010) Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy. J Ocul Pharmacol Ther 26:91-95
32. Hirami Y, Tsujikawa A, Otani A, Yodoi Y, Aikawa H, Mandai M, Yoshimura N (2007) Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 27:335-341 (Pubitemid 46398898)
33. Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ (2009) Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology 116:1755-1761
34. Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, Weisberger A, Lim TH (2012) EVEREST STUDY: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina Mar 21 [Epub ahead of print]